Preventive Effectiveness of Aspirin on Recurrent Stroke

Ya Fang Shiau, Chaur Jong Hu, Chuang Chin Chiueh

研究成果: 雜誌貢獻文章同行評審

2 引文 斯高帕斯(Scopus)

摘要

Multiple randomized trials indicated that antiplatelet agents, including aspirin alone, clopidogrel alone, and combined aspirin plus extended-release dipyridamole, can prevent recurrent stroke effectively. Previous findings indicated that aspirin plus extended-release dipyridamole is more effective than aspirin alone for the secondary prevention of stroke. Clopidogrel has been thought as effective as aspirin in the prevention of recurrent stroke. Thus, aspirin plus extended-release dipyridamole has been suggested to be superior to clopidogrel alone for preventing recurrent stroke based on indirect meta-analysis. However, the first clinical trial comparing aspirin plus extended-release dipyridamole and clopidogrel monotherapy directly revealed that aspirin plus extended-release dipyridamole is not different with clopidogrel alone in the risk of recurrent stroke significantly, which is not accordant to the early reports. Therefore, it is not known whether the more expensive agents like aspirin plus extended-release dipyridamole and clopidogrel could reduce the risk of recurrent stroke more effectively than aspirin alone. The 2011 American Heart Association/American Stroke Association guideline showed that aspirin alone, aspirin plus extended-release dipyridamole, and clopidogrel alone are acceptable choice for preventing recurrent stroke, but without a strong suggestion of preference. However, the 2012 update of the American College of Chest Physicians guideline indicated the superiority of aspirin plus dipyridamole for the secondary prevention of stroke compared with aspirin alone, but with a question about the truly beneficial effects on recurrent stroke with aspirin plus dipyridamole. A recent retrospective analysis of large patient numbers from Taiwan Stoke Registry (N = 10,792) indicated that aspirin regimen is not inferior to those more expensive agents such as aspirin plus dipyridamole or clopidogrel alone. In conclusion, based on the well-known efficacy and relative low cost, aspirin is effective as initial antiplatelet therapy for the secondary prevention of stroke in patients with ischemic stroke or transient ischemic attack.

原文英語
頁(從 - 到)203-208
頁數6
期刊Journal of Experimental and Clinical Medicine(Taiwan)
4
發行號4
DOIs
出版狀態已發佈 - 八月 2012

ASJC Scopus subject areas

  • 醫藥 (全部)

指紋

深入研究「Preventive Effectiveness of Aspirin on Recurrent Stroke」主題。共同形成了獨特的指紋。

引用此